Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing

Sophia Genetics

SOPHiA GENETICS technology will help increase cancer research abilities BOSTON and LAUSANNE, Switzerland, May 16, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Natural State Laboratories, a private, full-service, state-of-the-art molecular laboratory based in Little Rock, Arkansas, has chosen SOPHiA GENETICS …

Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing Read More »

For Immediate Release

NetGuardians

Swissquote chooses AI fintech NetGuardians to fight financial crime Yverdon-les-Bains, 9th May 2023: Swissquote, Switzerland’s leading online bank, has chosen NetGuardians to enhance fraud mitigation and comply with the AML requirements. The NetGuardians AI-based financial crime solutions will monitor all transactions at the bank and on the digital finance app ‘Yuh’, a joint venture between …

For Immediate Release Read More »

Dasa Expands Its Capabilities with SOPHiA GENETICS

Sophia Genetics

In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed  BOSTON and LAUSANNE, Switzerland, May 8, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 …

Dasa Expands Its Capabilities with SOPHiA GENETICS Read More »

AI/ML adoption in banking has started. Better collaboration should be next

NetGuardians

Artificial intelligence (AI) and machine learning (ML) are effective tools to combat fraud in retail banking. Raffael Maio from NetGuardians tells Sorin Dojan how his company plans to elevate the fight against financial crime. AI/ML is currently posing challenges for regulators and governments worldwide. Countries grapple with new uncharted territory following the recent launches of …

AI/ML adoption in banking has started. Better collaboration should be next Read More »

transmutex - 4seeventures

The best team ever !

Transmutex

How we have grown of over the last two years ! Time really flies. We are blessed to have been joined by a group of incredibly talented engineers, scientists, and administrators. Now almost 40 team members, 28 with a Ph.D., and 1/3 women, all focused on reinventing nuclear for the better of human civilization. Thank …

The best team ever ! Read More »

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

Stalicla

The combination of STALICLA and Firefly Neurosciences’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients.   Geneva, Switzerland – 27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). …

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD Read More »

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

Stalicla

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder. Agreement follows STALICLA’s recent in-licencing of mavoglurant from Novartis.   Geneva, Switzerland – 8 March 2023, STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform …

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder Read More »